Literature DB >> 15644185

Paradigms for conditional expression of RNA interference molecules for use against viral targets.

David S Strayer1, Mark Feitelson, Bill Sun, Alexey A Matskevich.   

Abstract

The rapid increase in the study of small interfering RNA (siRNA) as a means to decrease expression of targeted genes has led to concerns about possible unexpected consequences of constitutive siRNA expression. We therefore devised a conditional siRNA expression system in which siRNA targeting hepatitis C virus (HCV) would be produced in response to HCV. We found that HCV acts via NFkappaB to stimulate the HIV long terminal repeat (LTR) as a promoter. We exploited this observation by designing conditional siRNA transcription constructs to be triggered by HCV-induced activation of NFkappaB. These were delivered by using highly efficient recombinant Tag-deleted SV40-derived vectors. Conditional activation of HIV-LTR and consequent siRNA synthesis in cells expressing HCV were observed. HCV-specific RNAi decreased HCV RNA greatly within 4 days, using transient transfection of the whole HCV genome as a model of acute HCV entry into transduced cells. We then tested the effectiveness of rSV40-delivered anti-HCV siRNA in cells stably transfected with the whole HCV genome to simulate hepatocytes chronically infected with HCV. There is considerable need for regulated production of siRNAs activated by a particular set of conditions (HCV in this case) but quiescent otherwise. Approaches described here may serve as a paradigm for such conditional siRNA expression.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15644185     DOI: 10.1016/S0076-6879(04)92014-9

Source DB:  PubMed          Journal:  Methods Enzymol        ISSN: 0076-6879            Impact factor:   1.600


  6 in total

Review 1.  Long-term gene expression in dividing and nondividing cells using SV40-derived vectors.

Authors:  David S Strayer; Lokesh Agrawal; Pierre Cordelier; Bianling Liu; Jean-Pierre Louboutin; Elena Marusich; Hayley J McKee; Carmen N NiGongyi Ren; Marlene S Strayer
Journal:  Mol Biotechnol       Date:  2006-10       Impact factor: 2.860

Review 2.  Antiviral RNAi: translating science towards therapeutic success.

Authors:  Priya S Shah; David V Schaffer
Journal:  Pharm Res       Date:  2011-08-09       Impact factor: 4.200

Review 3.  Antiviral RNAi therapy: emerging approaches for hitting a moving target.

Authors:  J N Leonard; D V Schaffer
Journal:  Gene Ther       Date:  2006-03       Impact factor: 5.250

Review 4.  Combinatorial RNAi: a winning strategy for the race against evolving targets?

Authors:  Dirk Grimm; Mark A Kay
Journal:  Mol Ther       Date:  2007-02-20       Impact factor: 11.454

5.  Gene silencing in the therapy of influenza and other respiratory diseases: Targeting to RNase P by use of External Guide Sequences (EGS).

Authors:  David H Dreyfus; S Mark Tompkins; Ramsay Fuleihan; Lucy Y Ghoda
Journal:  Biologics       Date:  2007-12

6.  A hybrid CMV-H1 construct improves efficiency of PEI-delivered shRNA in the mouse brain.

Authors:  Zahra Hassani; Jean-Christophe François; Gladys Alfama; Ghislaine Morvan Dubois; Mathilde Paris; Carine Giovannangeli; Barbara A Demeneix
Journal:  Nucleic Acids Res       Date:  2007-04-10       Impact factor: 16.971

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.